Genmab A/S (NASDAQ:GMAB) Stock Keeps "Buy" Rating at Truist Financial

Key Points

• Truist Financial reaffirmed its “Buy” rating on Genmab and raised its price target from $45 to $67, implying 16.73% upside from the prior close.
• Analyst sentiment remains positive, with Genmab holding a consensus “Moderate Buy” rating and an average price target of $49.06; JPMorgan and Guggenheim also recently issued favorable updates.
• Genmab reported quarterly EPS of $0.54, exceeding the $0.37 consensus estimate, while revenue reached $1.16 billion. The stock recently traded at $57.40, near its 52-week high of $59.97.

Genmab A/S (NASDAQ:GMAB - Get Free Report)'s stock had its "buy" rating reaffirmed by equities researchers at Truist Financial in a research note issued on Thursday, Benzinga reports. They presently have a $67.00 price objective on the stock, up from their previous price objective of $45.00. Truist Financial's target price would suggest a potential upside of 16.73% from the company's previous close.

Other equities research analysts have also recently issued reports about the stock. Morgan Stanley set a $42.00 price target on shares of Genmab A/S in a report on Tuesday, October 20th. Weiss Ratings raised shares of Genmab A/S from a "hold (c)" rating to a "hold (c+)" rating in a research report on Tuesday, September 1st. Guggenheim increased their price objective on shares of Genmab A/S from $45.00 to $54.00 and gave the stock a "buy" rating in a research report on Monday, October 5th. JPMorgan Chase & Co. upgraded Genmab A/S from a "neutral" rating to an "overweight" rating in a research note on Monday. Finally, New Street Research set a $43.00 target price on Genmab A/S in a research report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $49.06.

Genmab A/S Trading Up 0.2%

GMAB stock traded up $0.10 during mid-day trading on Thursday, reaching $57.40. The company's stock had a trading volume of 3,078,609 shares, compared to its average volume of 2,431,813. Genmab A/S has a 12 month low of $23.62 and a 12 month high of $59.97. The company has a current ratio of 2.46, a quick ratio of 2.44 and a debt-to-equity ratio of 0.81. The business's 50 day moving average price is $36.20 and its 200 day moving average price is $30.36. The company has a market cap of $35.82 billion, a price-to-earnings ratio of 45.10, a price-to-earnings-growth ratio of 2.01 and a beta of 0.81.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.37 by $0.17. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.12 billion. On average, equities research analysts predict that Genmab A/S will post 1.22 EPS for the current year.

Institutional Trading of Genmab A/S

Institutional investors and hedge funds have recently modified their holdings of the business. First Trust Advisors LP increased its stake in shares of Genmab A/S by 84.3% in the 1st quarter. First Trust Advisors LP now owns 2,461,342 shares of the company's stock worth $66,038,000 after purchasing an additional 1,126,069 shares in the last quarter. Renaissance Technologies LLC lifted its position in Genmab A/S by 26.4% during the first quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company's stock valued at $118,442,000 after purchasing an additional 921,700 shares in the last quarter. SummitTX Capital L.P. bought a new stake in Genmab A/S during the first quarter valued at about $2,263,000. Legacy Wealth Asset Management LLC grew its holdings in Genmab A/S by 164.1% during the second quarter. Legacy Wealth Asset Management LLC now owns 102,164 shares of the company's stock valued at $2,806,000 after purchasing an additional 63,484 shares during the period. Finally, Advisors Preferred LLC purchased a new stake in Genmab A/S in the first quarter worth about $1,361,000. 7.07% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Genmab A/S

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: Major Phase 3 success: Genmab reported that the LiGeR-HN1 trial met both primary endpoints. Petosemtamab combined with Merck’s pembrolizumab (Keytruda) reduced the risk of death by 50% versus pembrolizumab alone in first-line, PD-L1-positive recurrent or metastatic head and neck cancer, while also improving objective response rates. Genmab Phase 3 trial announcement
• Positive Sentiment: Potentially practice-changing results: Coverage characterized the results as a significant advance, with analysts highlighting the combination’s statistically significant and clinically meaningful survival benefit. The data could support regulatory submissions and establish petosemtamab as a new treatment option if confirmed in the full dataset and accepted by regulators. Barron's petosemtamab coverage
• Positive Sentiment: Higher analyst valuation: HC Wainwright raised its Genmab price target from $50 to $70 and upgraded the stock to “buy,” implying approximately 23% upside from the reference price. JPMorgan also upgraded its rating, while TD Cowen said the shares could continue to rise.
• Positive Sentiment: Strong investor positioning: Reports of unusually high call-option activity indicate increased speculative and bullish interest following the trial announcement. Genmab call-option activity
• Neutral Sentiment: Risks remain: Petosemtamab is investigational, and Genmab still needs to discuss the results with regulators and submit the complete data for presentation and potential filings. The stock’s rapid move toward its 52-week high may also increase volatility and profit-taking risk.

About Genmab A/S

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system or target specific disease-related proteins.

Genmab's marketed and partnered products include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; EPKINLY (epcoritamab) for certain types of B-cell lymphoma, developed with AbbVie; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Seagen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.